Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Friedrich Stölzel, MD, Michael Kramer, Brigitte Mohr, PhD, Martin Wermke, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 1715.

https://doi.org/10.1182/blood.V120.21.1715.1715

Published: 2012

Journal Articles

Functional Influence of CXCL12 Regulating miRNAs in Mesenchymal Stem Cells (MSCs).

Laleh S. Arabanian, Fernando Fierro, David M. Poitz, PhD, Ruth H. Strasser, MD, Martin Bornhaeuser, MD, Gerhard Ehninger, Friedrich Stölzel, MD, Thomas Illmer

Blood (2012) 120 (21): 2350.

https://doi.org/10.1182/blood.V120.21.2350.2350

Published: 2012

Journal Articles

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Friedrich Stölzel, MD, David M. Poitz, PhD, Laleh S. Arabanian, Jens Friedrichs, PhD, Denitsa Docheva, PhD, Matthias Schieker, MD, Fernando A. Fierro, PhD, Uwe Platzbecker, MD, Ruth H. Strasser, MD, Martin Bornhäuser, MD, Carsten Werner, PhD, Gerhard Ehninger, Thomas Illmer, MD

Blood (2012) 120 (21): 3459.

https://doi.org/10.1182/blood.V120.21.3459.3459

Published: 2012

Journal Articles

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

Stefanie Göllner, PhD, Tino Schenk, PhD, Christian Rohde, PhD, Arthur Zelent, PhD, Friedrich Stölzel, MD, Christian Thiede, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 3468.

https://doi.org/10.1182/blood.V118.21.3468.3468

Published: 2011

Journal Articles

Regulatory Potential of miRNAs on CXCL12 Expression in Human Mesenchymal Stem Cells (MSC)

Thomas Illmer, Carolin Heder, Friedrich Stölzel, MD, Fernando Fierro, Gerhard Ehninger, MD

Blood (2011) 118 (21): 1332.

https://doi.org/10.1182/blood.V118.21.1332.1332

Published: 2011

Journal Articles

The Incidence of Central Nervous System Involvement in AML: A SAL-Tor Vergata Analysis

Nael Alakel, MD, Maria Ilaria Del Principe, Friedrich Stölzel, MD, Brigitte Mohr, Uta Oelschlaegel, PhD, Sergio Amadori, MD, Gerhard Ehninger, MD, Adriano Venditti, M.D., Markus Schaich, MD

Blood (2011) 118 (21): 4236.

https://doi.org/10.1182/blood.V118.21.4236.4236

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 493.

https://doi.org/10.1182/blood.V118.21.493.493

Published: 2011

Journal Articles

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

Friedrich Stölzel, MD, Christoph Röllig, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Jörgen Radke, Christian Thiede, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2010) 116 (21): 2154.

https://doi.org/10.1182/blood.V116.21.2154.2154

Published: 2010

Journal Articles

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

Friedrich Stölzel, MD, Klaus Zoephel, Christoph Röllig, Jörgen Radke, Johannes Schetelig, Uwe Platzbecker, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Jörg Kotzerke, Markus Schaich, MD

Blood (2010) 116 (21): 2156.

https://doi.org/10.1182/blood.V116.21.2156.2156

Published: 2010

Journal Articles

Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial

Christoph Röllig, Michael Kramer, Mathias Hanel, MD, Regina Herbst, Norbert Schmitz, MD, Heinrich Bodenstein, Karl-Heinz Pflüger, Thomas Wagner, Martin Wolf, MD, Martin Bornhäuser, Christian Thiede, MD, Markus Schaich, MD, Uwe Platzbecker, Friedrich Stölzel, MD, Malte von Bonin, Hannes Wandt, MD, Gerhard Ehninger, Ulrich Schuler

Blood (2010) 116 (21): 334.

https://doi.org/10.1182/blood.V116.21.334.334

Published: 2010

Journal Articles

Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.

Friedrich Stölzel, Walter E. Aulitzky, Heinrich Bodenstein, Martin Bornhäuser, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Norbert Schmitz, Silke Soucek, Christian Thiede, Gerhard Ehninger, Markus Schaich

Blood (2009) 114 (22): 2652.

https://doi.org/10.1182/blood.V114.22.2652.2652

Published: 2009

NARROW

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Functional Influence of CXCL12 Regulating miRNAs in Mesenchymal Stem Cells (MSCs).

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11,

Regulatory Potential of miRNAs on CXCL12 Expression in Human Mesenchymal Stem Cells (MSC)

The Incidence of Central Nervous System Involvement in AML: A SAL-Tor Vergata Analysis

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia

Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial

Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only